ARTICLE | Product Development

A Different Kettle of Fish

Taking on Lovaza: Amarin's AMR101 doesn't increase LDL cholesterol

December 6, 2010 8:00 AM UTC

Very high triglyceride levels can be controlled with purified omega-3 fatty acids and fibrates, but these therapies can also lead to significant elevation in LDL cholesterol, requiring the addition of a statin. Amarin Corp. plc believes its omega-3 product, AMR101, could be best in class based on Phase III data showing significant triglyceride reduction without an increase in LDL-C in patients with severe hypertriglyceridemia.

Next year, the company expects data from a second Phase III trial and a possible NDA submission...